Both luteolin and apigenin can inhibit STAT3 phosphorylation in non-small cell lung cancer (NSCLC) cells, down-regulate IFN-γ-induced PD-L1 expression, increase the activity and function of CD8+ T cells, and enhance the infiltration of CD8+ T cells in tumors (84). Here, CD8A is linked to non-small cell lung carcinoma.